Key Takeaways: The PSMA PET scan (68Ga PSMA PET/CT) has revolutionised prostate cancer staging, restaging, and theranostic selection. It detects prostate cancer with unmatched sensitivity — even at PSA levels below 0.2 ng/mL — and outperforms conventional CT and bone scan in virtually every clinical scenario. Neurad Diagnostics offers daily 68Ga PSMA PET/CT via its in-house Gallium Generator, delivering fast access and expert reporting for all stages of prostate cancer management.
PSMA PET Scan: What It Is and Why It Has Changed Prostate Cancer Diagnosis
The PSMA PET scan — formally known as 68Ga-PSMA PET/CT (Prostate-Specific Membrane Antigen Positron Emission Tomography / Computed Tomography) — is a molecular imaging technology that detects prostate cancer cells wherever they exist in the body by targeting a protein called Prostate-Specific Membrane Antigen. PSMA is expressed on the surface of virtually all prostate cancer cells at levels 100 to 1,000 times higher than in normal prostate tissue. This extraordinary selectivity means that when a 68Ga PSMA radioligand is injected intravenously, it circulates through the body and binds almost exclusively to prostate cancer deposits — making them light up brilliantly on PET imaging while surrounding normal tissue remains dark.
The clinical impact of the PSMA PET scan has been profound and swift. In the span of less than a decade, it has displaced conventional staging workup — CT abdomen/pelvis plus technetium bone scan — as the preferred imaging modality for high-risk and biochemically recurrent prostate cancer at leading cancer centres worldwide. The reason is simple: conventional imaging misses approximately 25–40% of metastatic deposits that PSMA PET/CT detects with ease, leading to fundamentally different and more accurate staging in a large proportion of patients.
Neurad Diagnostics provides daily access to 68Ga PSMA PET/CT through our in-house 68Ga Gallium Generator, which produces fresh radiopharmaceutical on demand without the delays and quality compromises associated with external supply. For patients and referring urologists, oncologists, and radiation oncologists, this means same-day or next-day appointments, consistent scan quality, and expert nuclear medicine reporting as the standard — not the exception.
How Does a PSMA PET Scan Work? The Science Explained Simply
The mechanism behind the PSMA PET scan can be understood in three steps. First, a small molecule ligand (PSMA-11 or PSMA-617) engineered to bind specifically to the PSMA protein is labelled with the radioactive isotope gallium-68 (68Ga). Second, this radiolabelled compound is injected intravenously, where it circulates in the bloodstream and selectively binds to PSMA-expressing cells — primarily prostate cancer cells. Third, the gallium-68 undergoes radioactive decay, emitting positrons that travel a short distance before annihilating with electrons to produce pairs of high-energy gamma rays. These gamma rays are detected by the PET scanner, which reconstructs their origin into a three-dimensional map of PSMA expression throughout the body.
The PET images are acquired simultaneously with a low-dose CT, which provides the anatomical “road map” onto which the functional PET data is overlaid. This fusion of molecular biology and anatomy gives the interpreting nuclear medicine physician an unparalleled composite picture: not just where cancer is located, but how metabolically active it is, how large the deposits are, and what structures they are adjacent to. The resulting report has direct, immediate implications for treatment decisions.
PSMA PET Scan Indications: When Should Your Patient Have One?
Primary Staging of High-Risk Prostate Cancer
For men with newly diagnosed high-risk or very high-risk prostate cancer (PSA above 20 ng/mL, Gleason Grade Group 4 or 5, or clinical stage T3/T4), PSMA PET/CT has become the recommended first-line staging modality at major cancer guidelines. The landmark proPSMA trial, published in The Lancet (2020), demonstrated that 68Ga PSMA PET/CT was 27% more accurate than conventional imaging for primary staging in high-risk prostate cancer, with 92% accuracy vs. 65% for CT plus bone scan. Furthermore, PSMA PET/CT changed treatment management in 28% of patients — meaning more than one in four high-risk patients received a fundamentally different (and presumably more appropriate) treatment plan when PSMA was used.
Biochemical Recurrence After Radical Prostatectomy
Biochemical recurrence — defined as a PSA rise to above 0.2 ng/mL after radical prostatectomy — affects approximately 20–40% of men treated surgically for prostate cancer. The critical question in this setting is whether the recurrence is local (in the prostate bed, salvageable with radiotherapy), regional (pelvic lymph nodes), or systemic (distant metastases, requiring systemic therapy). Answering this question with conventional imaging is often impossible at low PSA levels, whereas PSMA PET/CT has a positive detection rate of approximately 73–88% even when PSA is below 1.0 ng/mL, and up to 50% detection at PSA levels as low as 0.2–0.5 ng/mL. This guides salvage radiotherapy planning with precision that was previously unachievable.
Biochemical Recurrence After Radiotherapy
For men who develop PSA failure after primary radiotherapy (external beam or brachytherapy), PSMA PET/CT distinguishes between local recurrence in the prostate gland (potentially salvageable with radical prostatectomy or focal salvage ablation), regional nodal recurrence, and distant metastases. This distinction is clinically critical, as it determines whether a salvage curative approach is feasible or whether systemic androgen deprivation therapy (ADT) is indicated.
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
In the setting of mCRPC, PSMA PET/CT plays a pivotal role in selecting patients for 177Lu-PSMA radionuclide therapy — one of the most effective systemic treatments for this disease stage, approved by the FDA following the VISION trial. A pre-treatment PSMA PET/CT confirms that the patient’s disease is PSMA-positive and quantifies the extent of PSMA expression, which is the primary criterion for treatment eligibility. Neurad Diagnostics coordinates closely with treating oncologists to provide theranostic-intent PSMA PET/CT reports optimised for this specific purpose.
Oligometastatic Prostate Cancer
PSMA PET/CT has created the concept of “PSMA-defined oligometastatic prostate cancer” — a disease state where 1–5 metastatic lesions are identified by PSMA scanning and are potentially amenable to metastasis-directed therapy (MDT) with SBRT or lymph node dissection. Multiple prospective studies including the ORIOLE and STOMP trials have demonstrated oncological benefit from MDT in PSMA-detected oligometastatic disease, including delayed initiation of androgen deprivation therapy. Accurate lesion identification and characterisation through PSMA PET/CT at Neurad Diagnostics is the essential first step in this treatment paradigm.
PSMA PET Scan Preparation and Procedure: What to Expect
The PSMA PET scan at Neurad Diagnostics is a well-tolerated outpatient procedure with a typical total appointment duration of 2–3 hours. Preparation requirements are straightforward and are communicated to patients in writing at the time of booking.
PSMA PET Scan Preparation Guidelines
- Fasting: Fast for at least 4 hours before the injection. Water intake is encouraged — drink 500 mL of water in the hour before arriving.
- Medications: Continue all regular medications unless specifically advised otherwise. Unlike DOTANOC scans, no somatostatin analogue hold is required for PSMA.
- Activity: Avoid strenuous exercise for 24 hours before the scan, as muscular uptake of gallium tracers can occasionally complicate interpretation.
- Androgen deprivation therapy (ADT): There is evidence that PSMA expression increases with androgen deprivation, meaning patients on ADT may have more sensitive scans. Discuss the timing of ADT in relation to scanning with your oncologist.
- Clothing: Wear loose, comfortable clothing with no metal fasteners. Remove jewellery before arrival.
- Duration: Plan for 2–3 hours total: 15 minutes for check-in and IV insertion, 60–75 minutes uptake time after injection, 20–25 minutes for PET/CT scanning, 10 minutes for recovery and dressing.
Interpreting PSMA PET Scan Results: What the Report Tells Your Oncologist
PSMA PET/CT reports from Neurad Diagnostics are structured to provide referring clinicians with the maximum clinically actionable information. Each report includes a systematic anatomical survey of PSMA-avid findings, lesion characterisation (size, PSMA intensity as standardised uptake value [SUV]), anatomical localisation (using CT landmarks), and an overall PSMA PET/CT staging classification using the validated PROMISE (Prostate Cancer Molecular Imaging Standardised Evaluation) criteria.
The PROMISE framework assigns each patient to one of five miTNM categories reflecting local, nodal, and metastatic disease extent as detected by PSMA PET/CT. This standardised reporting enables consistent communication between nuclear medicine and the treating team, reproducible documentation for clinical trials, and quantitative disease burden assessment for tracking treatment response on follow-up scans. [Insert External Link to PROMISE criteria publication, European Journal of Nuclear Medicine]
PSMA PET Scan vs. Conventional Staging: The Evidence is Clear
The evidence supporting PSMA PET/CT over conventional imaging for prostate cancer is now so robust that multiple national and international guidelines — including those from the European Association of Urology (EAU), the American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) — have incorporated PSMA PET/CT as a preferred or recommended investigation for high-risk and recurrent prostate cancer. The speed of this guideline adoption, from initial research to mainstream recommendation, reflects the magnitude of the clinical benefit demonstrated in prospective trials.
Key performance differences documented in the literature include: sensitivity of 91% vs. 59% for pelvic nodal metastasis detection; detection rate of 70–88% for biochemical recurrence at PSA below 1.0 ng/mL vs. less than 30% for conventional imaging; and upstaging of 16–33% of patients with primary high-risk disease. Each of these improvements translates into clinical benefit: more patients receive appropriately tailored treatment, fewer patients undergo unnecessary extensive surgery or radiotherapy, and more patients are correctly identified as candidates for systemic or theranostic therapies. [Insert External Link to EAU prostate cancer guidelines on PSMA PET/CT, uroweb.org]
Frequently Asked Questions: PSMA PET Scan for Prostate Cancer
What is the difference between a PSMA PET scan and a bone scan?
A conventional technetium-99m bone scan detects increased osteoblastic activity (bone remodelling) at metastatic sites and is entirely non-specific — it can be positive in arthritis, fractures, and Paget’s disease. PSMA PET/CT directly images the prostate cancer cell biology regardless of anatomical site — detecting nodal, visceral, bone, and soft tissue metastases with equal sensitivity. PSMA PET/CT detects bone metastases that bone scans miss, and is positive in pure lytic lesions (common in later-stage prostate cancer) where bone scans are frequently false-negative.
How high does PSA need to be for a PSMA PET scan to be positive?
PSMA PET/CT has positive detection rates of approximately 50–73% at PSA levels of 0.2–1.0 ng/mL and rises steeply above PSA 1.0 ng/mL, reaching over 90% at PSA above 2.0 ng/mL. Importantly, even a negative PSMA scan at low PSA provides clinically useful information — the absence of macroscopic distant metastases supports a salvage radiotherapy approach, which is guided by the scan result regardless of whether disease is visualised or not.
Is the PSMA PET scan safe?
68Ga PSMA PET/CT has an excellent safety profile. The gallium-68 isotope has a half-life of 68 minutes, so radiation exposure is brief and self-limiting. No serious adverse events have been reported in the extensive worldwide clinical experience with this agent. The total effective radiation dose is comparable to or less than that of a diagnostic CT scan.
How do I book a PSMA PET scan at Neurad Diagnostics?
PSMA PET/CT is available daily at Neurad Diagnostics via our in-house 68Ga Gallium Generator. Appointments can be made by telephone, online booking portal, or through our physician referral line. A valid clinical referral from a urologist, oncologist, or radiation oncologist is required. Same-day and next-day appointments are frequently available. [Insert Internal Link to Appointment Booking Page] [Insert Internal Link to Physician Referral Page]
Why Neurad Diagnostics Is the Premier Destination for PSMA PET Scans
The PSMA PET scan is only as good as the facility that performs it. The quality of the radiopharmaceutical, the performance specifications of the PET/CT scanner, and the expertise of the nuclear medicine physician interpreting the images all directly determine the clinical value of the result. At Neurad Diagnostics, we have invested in each of these critical determinants: an in-house 68Ga Gallium Generator producing daily high-purity PSMA radioligand, a state-of-the-art PET/CT scanner with high time-of-flight sensitivity, and a nuclear medicine reporting team with extensive experience in prostate cancer imaging and PSMA PET/CT interpretation.
Our PSMA PET scan reports are structured to meet the clinical needs of the multidisciplinary prostate cancer team — with systematic anatomical coverage, standardised PROMISE reporting, and SUV quantification that enables direct comparison on follow-up studies. For any patient with prostate cancer where staging, restaging, or theranostic workup is required, Neurad Diagnostics is your partner in precision oncology. [Insert Internal Link to Contact Page]